Skip to content
zameds

Nilotinib (Tasigna, Pantrello)

Nilotinib

Novartis South Africa (Pty) Ltd

S4

Registration

Applicant
Novartis South Africa (Pty) Ltd
Registrations
4
Schedule source
Consolidated Schedules 06 July 2026

Variants

ProductStrength and formRegistrationStatusScheduleLeaflets
Tasigna 200 MG

EACH CAPSULE CONTAINS: NILOTINIB HYDROCHLORIDE MONOHYDRATE EQUIVALENT TO NILOTINIB 200,0 mg

200 mg41097341/26/0973RegisteredS4None
Tasigna 150 MG

EACH CAPSULE CONTAINS: NILOTINIB HYDROCHLORIDE MONOHYDRATE EQUIVALENT TO NILOTINIB 150,0 mg

150 mg45041045/26/0410RegisteredS4None
Pantrello 150 MG

EACH CAPSULE CONTAINS: NILOTINIB HYDROCHLORIDE EQUIVALENT TO NILOTINIB 150,0 mg

150 mg50045250/26/0452RegisteredS4None
Pantrello 200 MG

EACH CAPSULE CONTAINS :NILOTINIB HYDROCHLORIDE EQUIVALENT TO NILOTINIB 200,0 mg

200 mg50045350/26/0453RegisteredS4None

Regulatory status

Where S4 sits on the scale

Prescription-only medicine.

Schedule 4 covers most ordinary prescription medicines. You need a prescription from an authorised prescriber, such as a doctor or dentist, and a pharmacist dispenses it. Its price, name, pack size and strength can still be told to the public, as long as nothing links it to what it treats.

Schedule S4, matched to the Consolidated Schedules by ingredient, confidence high.

Who may supply: A pharmacist dispensing against a written or verbal prescription from an authorised prescriber; a veterinarian, who may also prescribe, compound or dispense it directly; a medical practitioner or dentist, who may prescribe it and may compound or dispense it directly only if licensed under section 22C(1)(a); manufacturers and wholesalers may supply people who may lawfully possess it; and, for animal treatment, a person practising a para-veterinary profession, on a veterinarian's written or verbal instruction.

Consolidated Schedules listings for Nilotinib

  • S4: Nilotinib

    Consolidated Schedules 06 July 2026, line 7267

Pharmacological class: Cytostatic agents (class 26)

This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.

C28H22F3N7O529.50 g/mol

4-Methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide

Drag to rotate. Structure from PubChem CID 644241.

SAHPRA documents

SAHPRA has not published a professional information or patient information leaflet for this product.

Background

Loading...
Loading Wikipedia summary

Research articles

Loading...
Loading PubMed articles